Welcome to the business of printing money $$$ Good Morning Fellow Aristocrats,
First off, to those of you on Friday who were about ready to take tripps head off and parade it down wall street.... I felt that too.
But then like all of you, had the weekend to think about it and came to the conclusion
"our only saving grace is if Monday SZLS comes out with Great news"
Boy did they deliver!
Look at these statements!
The Company has received revenue from performing COVID-19 testing during Q2 2020 and this continues into Q3 2020. This is in contrast to many other labs whose testing requests have essentially ceased. The Telehealth Platform that was created to support the Company's cancer screening tests has proven fundamental to facilitating COVID-19 testing. Initial interest received by the Company represented approximately US$18M+ in revenue. The Company is working to increase its processing capabilities and has received new orders.
The following milestones were achieved during the second quarter:
- Pivoted the full lab and initiated COVID-19 testing with PCR and Antibodies
- Partnered with 5 initial groups
- City of Alpharetta offered StageZero COVID-19 testing to its first responders
- Partnership with UDo Test connected the Company to a network of 50,000 physicians
- Mercer VIP Program included StageZero COVID-19 testing and connected the company to numerous employers who have ordered tests. StageZero is now a preferred lab for Mercer.
- Closed $4.6M in financing via a prospectus offering
- Hired additional staff, purchased equipment, test reagents, and consumable materials (for COVID-19 Tests and Aristotle®).
The following has been achieved in the six weeks post the second quarter:
- Received revenue of approximately $1 million
- Signed multiple new partners. These include a County in a hotspot State; three healthcare groups; an airline; several travel groups with exposure to the airlines.
- Expanded testing in Canada via the partnership with Ichor Blood Services
- Hired further staff and expanded testing capacity, both for COVID-19 and Aristotle.
The Company is using the recent increased exposure of its capabilities to highlight its core cancer screening business and build long term relationships with healthcare systems and large employers. This in preparation for Aristotle.
"The COVID-19 pandemic has severely impacted many diagnostic labs. Our ability to pivot quickly during Q2, and to initiate both PCR and antibody COVID-19 testing to survive an unprecedented downturn is testimony to our group's ability to innovate", said James Howard-Tripp, Chairman and CEO. "It is now for us to use the opportunity to springboard into the launch of Aristotle and to use the incremental revenue and new partnerships we are building".
Then on top of that, Dr Tripp himself during his Call in session was dropping BOMBS on us.
"more revenue in 6 weeks then in the last 6 years" was my absolute favorite.
That just stamped this companies future into high gear.
Like I have said this whole time,
There is a reason why institutional investors gave them 4.6 million dollar investment.... no one gives away money like that especially during a pandemic.
They must have had the same kind of revenue projection spreadsheets like the ones ive been posting on here since their prospectus came out.
For the Gentleman who Called me out on friday saying "Wheres the spreadhseet now and comments saying following prospectus to a T"
WE WERE RIGHT!
this company is going to climb and climb until it reaches the famous B word Valuation that is now being mentioned.
Aristotle is going to lift this company to the moon
I am going to leave my last comments on here until I receive my invitation to puppy Yacht Island where I am going to wear an assortment of t shirts with these comments written on them
"Becky Where Is My Appology"
"Congrats to everyone who bought at at these levels"
"We are in the business of printing money"
Cheers,
Bully